Almac Group has unveiled a $48 million investment aimed at advancing eClinical technologies, highlighted by the debut of its new interoperable platform, Almac Trial Coordinator™. This first-in-class solution is designed to help sponsors, contract research organizations (CROs), and clinical trial sites manage increasingly complex studies with greater efficiency.
The Almac Trial Coordinator™ platform addresses common challenges in clinical trials, particularly the fragmentation of systems and data across various providers. By unifying operational processes and clinical data into one protocol, the technology enables standardization while maintaining flexibility, thus supporting different trial requirements without the constraints of vendor lock-in. The system’s open APIs and standards-based exports allow for integration with modern technology stacks and facilitate rapid, low-disruption amendments to protocols.
Usability features include role-based interfaces, two-tap onboarding, multilingual support available around the clock, and built-in localization and compliance validation. The platform also features robust data provenance and reusable libraries of standardized study templates, which help accelerate trial setup and maintain quality standards.
Almac’s investment will create over 100 advanced technology positions worldwide, reflecting its broader strategy to enhance both site and sponsor capabilities in conducting high-quality, large-scale clinical trials. Company executives emphasized that improved interoperability and streamlined processes are intended to meet the changing needs of the global clinical research field while supporting improved patient engagement and risk management.